This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary FRα Therapeutic Antibody Development
FRα is a promising and emerging cancer treatment drug target. The development of therapeutic antibodies targeting specific biomarkers is demonstrating great therapeutic potential in the current field of veterinary medicine. BioVenic offers comprehensive veterinary FRα therapeutic antibody development services. Our services range from gene synthesis and antibody production to subsequent purification and testing processes, covering full aspects of the development process, thereby facilitating the smooth advancement of veterinary FRα therapeutic antibody development projects.
Background of FRα
| Full Name | Folate receptor alpha |
|---|---|
| Aliases | FBP, FOLR, FOLR1, FRalpha, NCFTD. |
| Target Profile | FRα is a glycosylphosphatidylinositol (GPI) anchored membrane protein encoded by the FOLR1 gene. FRα binds with high affinity to folic acid and its derivatives, mediating cell division, proliferation, and tissue growth through signal cascades and as a component of the folate cycle. Therefore, its overexpression may confer a growth advantage to tumors by increasing folate uptake, playing a role in tumor cell migration and invasion. |
MoA of FRα
FRα is a folate transport protein that internalizes folate. Folate binds with FRα to form a complex, which is then transported into the cell through a specific endocytosis pathway, facilitating the release of folate for one-carbon metabolism in this process. In various solid tumors, the overexpression of FRα is closely associated with the development of cancer, enhancing ERK-STAT3 signaling and playing a role in regulating the invasive and metastatic characteristics of cancer cells. FRα can translocate to the cell nucleus, acting as a transcription factor that affects the expression of crucial developmental genes. Additionally, the uptake and internalization of folate via FRα are related to cancer cell characteristics such as proliferation, migration, and disrupted adhesion. FRα has also been found to affect the expression of the intercellular adhesion molecule E-cadherin, which is inversely related to the survival rate of cancer patients.
Fig.1 Schematic diagram of FRα-mediated folate internalization and its regulation of cancer signaling.1
Application in Veterinary Therapeutics
Non-reduced folates are utilized by tumor cells, typically transported through high-affinity folate receptors (FR), mainly FRα in solid tumors. Companion animal cancer types, such as canine invasive urothelial carcinoma, have been found to express high levels of FRα. Considering veterinary therapeutic antibodies targeting FRα, there is potential to regulate folate-dependent growth in FRα-transfected cells and mediate tumor cell cytotoxicity through CDC and ADCC. These antibodies preferentially bind to tumor cells of selected cancer types while largely sparing normal tissues.
Veterinary FRα Therapeutic Antibody Development Services
FRα is a key biomarker, especially expressed in various solid tumors. BioVenic offers veterinary FRα therapeutic antibody development services. Utilizing our technology, we have the capability to assist in developing antibodies targeting FRα for the treatment of specific types of companion animal cancers. Our services encompass the entire process from target identification to antibody design, expression, purification, and functional validation, ensuring that the antibodies have high affinity and specificity, and are capable of effectively recognizing and binding to FRα.
To learn more about our veterinary FRα therapeutic antibody development services, please click the link below.
Why Choose Us?
BioVenic offers a one-stop service, covering from initial gene synthesis and animal immunization to later stages of antibody preparation, purification, and characterization in our veterinary therapeutic antibody development services.
Considering the uniqueness of different species, we provide customized solutions through species-specific antibody development to meet the varied needs of different species.
Throughout the process of assisting you in antibody development, we maintain strict quality control to ensure that the veterinary therapeutic antibody samples have high purity and stability.
The overexpression of FRα in various solid tumors can promote the development of cancer in different ways, especially in cancer types known for high FRα expression, such as canine invasive urothelial carcinoma. BioVenic offers veterinary FRα therapeutic antibody development services. Through our one-stop, high-quality service, we help you explore the potential of veterinary FRα therapeutic antibodies in the treatment of companion animal cancers, expanding the range of applicability of the antibodies to cover more types of cancers. If you have development needs in this area, please contact us now!
References
- Cheung, Anthony, et al. "Targeting folate receptor alpha for cancer treatment." Oncotarget 7.32 (2016): 52553.
- Dhawan, Deepika, et al. "Targeting folate receptors to treat invasive urinary bladder cancer." Cancer research 73.2 (2013): 875-884.